ARMP Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
3.2M
+26.3%
2.5M
+218.1%
789.0K
-27.3%
1.1M
-6.4%
1.2M
Cost of Revenue
0
0
0
0
0
Gross Profit
3.2M
+26.3%
2.5M
+218.1%
789.0K
-27.3%
1.1M
-6.4%
1.2M
Operating Expenses
10.6M
-17.7%
12.8M
+33.9%
9.6M
-35.8%
14.9M
+66.8%
8.9M
R&D
6.8M
-10.0%
7.6M
+24.1%
6.1M
+0.7%
6.1M
+4.2%
5.8M
SG&A
3.7M
-28.9%
5.2M
+51.2%
3.5M
+1.1%
3.4M
+10.1%
3.1M
Operating Income
-7383000
+28.4%
-10312000
-17.4%
-8785000
+36.4%
-13823000
-77.8%
-7776000
EBITDA
-6811000
+29.9%
-9721000
-16.7%
-8328000
-4.2%
-7993000
-7.9%
-7406000
Net Income
54.9M
-26.0%
74.1M
+164.3%
-115346000
+7.2%
-124298000
-366.0%
-26675000
EPS (Basic)
$1.15
-43.1%
$2.02
+163.9%
$-3.16
+7.6%
$-3.42
-362.2%
$-0.74
EPS (Diluted)
$-0.24
+11.1%
$-0.27
+91.5%
$-3.16
+66.8%
$-9.52
-1186.5%
$-0.74
Shares (Diluted)
62.7M
+1.0%
62.0M
+69.8%
36.5M
+179.7%
13.1M
-64.0%
36.2M
Armata Pharmaceuticals (ARMP) — Financials